Systemic sclerosis (SSc) is a poorly understood and relatively rare, but frequently fatal, illness involving widespread scarring and vascular disease. The Boston University Scleroderma Center of Research Translation is an outgrowth of a concerted and collaborative effort over the last 15 years to examine the pathogenesis of systemic sclerosis and its relationship to clinical disease expression. A five-year, $8 million grant from the National Institutes of Health’s National Institute of Arthritis and Musculoskeletal and Skin Diseases will enable the B.U. SSc CORT to coordinate multiple scientists and clinicians to accelerate understanding of the disease process through highly interactive patient-oriented studies into markers of disease activity, investigation of pathogenesis and trials of novel therapeutics.
The CORT Team